Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys has reported that Astellas Pharma has decided to extend the current collaboration between the two companies. The collaboration, originally signed in March 2007, will now run its full term.
Subscribe to our email newsletter
Now this agreement extended for four more years until March 2012, Astellas will continue to have access to MorphoSys’s proprietary antibody library HuCAL Gold at its research site in Tsukuba, Japan.
Furthermore, the extension includes an option for Astellas to develop and commercialize HuCAL-derived therapeutic antibodies, in which case MorphoSys would receive exclusive license fees, milestone payments, as well as royalties. Under the extended agreement MorphoSys continues to receive annual user fees for access to its HuCAL platform.